Phase 1 Dosing of Voriconazole Inhalation Powder up to 80 mg/dose in healthy subjects for direct-to-lung delivery of voriconazole for Invasive Pulmonary Aspergillosis (IPA) Phase 2 studies to commence, assessing the efficacy of the dry powder formulation for the treatment of IPA Company is

Panel discussion scheduled for Thursday, September 17, 2020 at 11:00 AM EDT AUSTIN, Texas --(BUSINESS WIRE)--Sep. 14, 2020-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented

Corporate presentation and live webcast scheduled for Monday, September 14, 2020 at 4:00 PM EDT AUSTIN, Texas --(BUSINESS WIRE)--Sep. 10, 2020-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products